SCHEDULE: Millennium Discloses 2.9% Stake in AnaptysBio

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander jointly reported a 2.9% beneficial ownership stake in AnaptysBio, Inc. as of December 31, 2025.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The filing reports beneficial ownership of Common Stock, par value $0.001 per share, of AnaptysBio, Inc.
• As of December 31, 2025, the Reporting Persons collectively beneficially owned 813,571 shares.
• This aggregate amount represents 2.9% of AnaptysBio, Inc.'s outstanding Common Stock.
• The Reporting Persons hold shared voting power and shared dispositive power over all 813,571 shares.
• The securities were not acquired and are not held for the purpose of changing or influencing the control of AnaptysBio, Inc.

Sentiment

Score: 5

Explanation: Neutral, as this is a routine disclosure of a passive investment stake by institutional investors, not an announcement of company performance, strategic changes, or operational updates.

Future Outlook

This filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding AnaptysBio, Inc.'s future performance or the Reporting Persons' investment intentions beyond the passive nature of the stake.

Industry Context

This filing represents a routine disclosure by a significant institutional investor, Millennium Management, of a passive stake in a publicly traded biotechnology company, AnaptysBio, Inc. Such disclosures are common and indicate an investment position below the 5% threshold that would typically trigger a more active Schedule 13D filing, reinforcing the passive nature of the investment.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, indicating a notable investor holds a passive stake in the company.

Key Dates

Keywords

AnaptysBio, Millennium Management, Israel Englander, Schedule 13G, beneficial ownership, common stock, institutional investment